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Abstract
Objectives: We aim to address several clinical interests regarding lung volume reduction surgery (LVRS) for severe
emphysema using meta-analysis and systematic review of randomized controlled trials (RCTs).
Methods: Eight RCTs published from 1999 to 2010 were identified and synthesized to compare the efficacy and
safety of LVRS vs conservative medical therapy. One RCT was obtained regarding comparison of median
sternotomy (MS) and video-assisted thoracoscopic surgery (VATS). And three RCTs were available evaluating clinical
efficacy of using bovine pericardium for buttressing, autologous fibrin sealant and BioGlue, respectively.
Results: Odds ratio (95%CI), expressed as the mortality of group A (the group underwent LVRS) versus group B
(conservative medical therapies), was 5.16(2.84, 9.35) in 3 months, 3(0.94, 9.57) in 6 months, 1.05(0.82, 1.33) in 12
months, respectively. On the 3
rd,6
th and 12
th month, all lung function indices of group A were improved more
significantly as compared with group B. PaO2 and PaCO2 on the 6
th and 12
th month showed the same trend.
6MWD of group A on the 6
th month and 12
th month were improved significantly than of group B, despite no
difference on the 3
rd month. Quality of life (QOL) of group A was better than of group B in 6 and 12 months.
VATS is preferred to MS, due to the earlier recovery and lower cost. And autologous fibrin sealant and BioGlue
seems to be the efficacious methods to reduce air leak following LVRS.
Conclusions: LVRS offers the more benefits regarding survival, lung function, gas exchange, exercise capacity and
QOL, despite the higher mortality in initial three postoperative months. LVRS, with the optimization of surgical
approach and material for reinforcement of the staple lines, should be recommended to patients suffering from
severe heterogeneous emphysema.
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Introduction
Emphysema is a chronic and progressive disease, charac-
terized by permanent impairment of pulmonary terminal
airway, hyperinflation of parenchyma and loss of elastic
retraction. The shortness of breath, poor exercise toler-
ance and impaired health status will occur on the final
stage of emphysema [1-3]. Thus far, the conservative
medical therapies (antibiotics, bronchodilators, systemic
corticosteroids, home oxygen therapy, pulmonary reha-
bilitation) still remain to be symptomatic treatment
rather than always due to failure to improve elastic
recoil of lung issue [2-5]. Lung volume reduction sur-
gery(LVRS), which was initially introduced in 1957 by
Brantigan [6] and developed by Cooper in 1993 [7],
resects diseased and non-function pulmonary issue in
order to ameliorate lung function, exercise capacity and
health status, by(1) increasing pulmonary elastic recoil,
therefore increasing expiratory airflow rates, (2) redu-
cing the degree of hyperinflation, therefore improving
mechanics of diaphragm and chest wall, (3) reducing
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improving of alveolar gas exchange [8].
Although numerous studies have addressed the
patients with severe emphysema can receive benefits
from LVRS, some physicians remain routinely reluctant
to recommend LVRS to the suitable patients due to the
insufficient published Randomized Clinical Trials
(RCTs) evaluating surgical risks and long term sequels
[9-12]. Besides, there are controversial points regarding
the efficacy and safety of two approaches for LVRS
[median sternotomy(MS) vs video-assisted thoracoscopy
surgery (VATS)] [13]. In addition, various materials
have been utilized to prevent air leak which is one of
the most crucial risk factors for LVRS [14,15], but the
efficacy should be assessed immediately. Herein, we per-
formed a meta-analysis of RCTs published in the past
11 years for the sake of evaluating safety, short-term
efficacy and long-term sequel of LVRS. And we conduct
the systematic review of two approaches (MS vs VATS)
and the materials (bovine pericardium for buttressing,
autologous fibrin sealant and BioGlue) for LVRS.
Materials and methods
We used systematic methods to identify relevant studies,
assess study eligibility, evaluate methodological quality,
and summarize findings regarding postoperative clinical
outcomes.
Data sources and searches
Medline and manual searches were performed by two
investigators independently and in duplicate to identify
all published RCTs during from 1999 year to 2010 year
that addressed the issue of LVRS for emphysema.
The Medline search was done on Pubmed (http://
www.ncbi.nlm.nih.gov), one set was created using the
medical subject headings (MeSH) term ‘pneumonect-
omy’ (18249 citations, March 31
st,2011) and another
was created using the MeSH term ‘pulmonary emphy-
sema’ (12953 citations, March 31
st, 2011). Combining
the two sets with the Boolean ‘and’ function yielded
1006 citations, This set was limited by the publication
type ‘randomized controlled trial’ to give 36 citations in
English. Manual searches were then done by reviewing
articles cited in the reference lists of identified RCTs,
and also by reviewing first author’s article.
Eight published RCTs [2,12,16-21] were identified
regarding LVRS vs conservative medical therapies (table
1). Among the eight RCTs, Pompeo’s article [17] and
Mineo’s article [20] were from the same trial. Pompeo’s
study [17] presented mortality, but “mean ± SD” of lung
function was missing, wheraes it was presented in
Mineo’s study. Therefore, we included both of the afore-
said articles. We did not include unpublished data
because of the limited number of RCTs, trials were not
excluded because of trial quality (design) or insufficient
number of patients. A trial quality score was assigned
(scale of 1-5) according to the method of Jadad et al
[22]. One investigator screened the articles and identi-
fied article abstracts for full review.
One RCT [13] regarding comparison of two
approaches for LVRS (MS vs VATS) was obtained. And
three RCTs [14,15,23] were available evaluating clinical
efficacy of using bovine pericardium for buttressing,
autologous fibrin sealant and BioGlue, respectively.
Data abstraction
Two investigators abstracted the following information
from the eligible articles without blinding: author, loca-
tion of study site, journal, year of publication, study
design, number of patients, demographic characteristics,
clinical outcomes, and follow-up period. In all of the
included articles, patients underwent LVRS. Major clini-
cal outcomes for quantitative data synthesis included
postoperative mortality, lung function, gas exchange
(PaO2 and PaCO2), DLCO, 6MWD. Disagreements were
resolved by consensus review with a third investigator.
Statistical analysis
Test- and study-specific estimates
Major postoperative outcomes are defined in the index
tests as follows:(1) Postoperative mortality in the 3, 6
and 12 months.(2) Postoperative Lung function on the
3
rd,6
th and 12
th month including FEV1, FEV1%, RV%
and TLC%.(3) gas exchange and DLCO% on the 6
th
and 12
th month.(4) Postoperative 6MWD on the 3
rd,
6
th and 12
th month.(5) QOL: We performed systematic
review, instead of meta-analysis of QOL in the RCTs
due to the different evaluating criterion including the
Sickness Impact Profile (SIP) scoring system [16], the
36-item short-Form Health-Related Questionnaire(SF-
36) [2,12,20,21], the Nottingham Health Profile (NHP)
[20], the St George’s Respiratory Questionnaire
(SGRQ) [2,20], Quality of Well-being scale [18] and
the Chronic Respiratory Questionnaire (CRQ) [19,21].
Meta-analysis model
A fixed-effect model was applied when the P values of
test for heterogeneity is more than 0.5. A random-
effects model was used as it provided conservative confi-
dence intervals for postoperative outcomes between
study variability (P < 0.05). Odds ratio or weighted
mean difference was the principal measure of effect.
They were presented as a point estimate with 95% confi-
dence intervals and P values in parentheses. Review
Manager 4.2.2 (The Cochrane Collaboration. Wintertree
Software inc, Canada) statistical software was used. Pub-
lication bias could not be properly assessed because
there were insufficient RCTs to construct a funnel plot.
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The two trial assessors agreed upon the identified and
selected RCTs. RCTs quality scores range from 3 to 5(5-
point scale). Trial assessor agreement on quality assess-
ment was strong (100%). Odds ratio (95% CI) for mortal-
ity, weighted mean difference for lung function (FEV1,
FEV1%,RV%,TLC%),gas exchange(PaO2,PaCO2), DLCO%
and 6MWD were depicted in Figures 1A-E and Table 2.
Meta-analysis of mortality of the group underwent LVRS
(group A, similar thereinafter) and the group received
conservative medical therapies (group B, similar
thereinafter) in 3,6 and 12 months
Odds ratio (95%CI), expressed as the mortality of group
A versus group B, was 5.16(2.84, 9.35) in 3 months, 3
(0.94, 9.57) in 6 months, 1.05(0.82, 1.33) in 12 months,
respectively.
Figure 1 A demonstrated that mortality in 3 months
was significantly lower in group B than in group A (test
for overall effect, Z = 5.4, P < 0.0001), as well as the
same trend on mortality in 6 months despite no statisti-
cal significance (Z = 1.86, P =0 . 0 6 )( F i g u r e1 B ) .H o w -
ever, there was no significant difference of mortality
between the two groups in 12 months (Figure 1C, test
for overall effect, Z = 0.36, P = 0.72). Additionally, we
got the same trend regarding the mortality in either 3
or 12 months (Figure 1D and 1E, Z = 2.35, P =0 . 0 2 ;Z
=1 . 5 8 ,P = 0.11, respectively) after excluded the results
from Fishman’s study which was an extremely large
sample trial and might result in the bias.
Meta-analysis of lung function, gas exchange and DLCO%
a nd 6MWD on the 3
rd,6
th and 12
th month
We conducted meta-analysis from six RCTs regarding
lung function, gas exchange and DLCO% and 6MWD
on the 3
rd,6
th,1 2
th month (Table 2). Two RCTs (Fish-
man A et al. [18] and Geddes et al [12]) were not
included without expression of “mean ± SD” of aforesaid
indices.
On the 3
rd,6
th and 12
th month, all lung function indices
of group A were improved more significantly compared
with group B (Table 2). PaO2 and PaCO2 on the 6
th and
12
th month were available in the RCTs, and either showed
t h es a m et r e n d( T a b l e2 ) .6 M W Do fg r o u pAo nt h e6
th
month and 12
th month were improved significantly than
of group B (Table 2), although there was no difference on
the 3
rd month.
Systematic review of QOL
The RCTs strongly suggested that QOL of group A was
better than of group B in the 6 and 12 months
[2,12,16-21] (Geddes’s study [12] indicated no difference
between the groups in 3 months). Besides, long-term
follow up also supported the aforementioned conclusion
[18,20] (Mineo et al. [20]: 48 months and Fishman A et
al. [18]: 24 months).
Comparison of two surgical approaches (MS vs VATS)
Only one RCT [13] regarding comparison of MS and
VATS indicated (1) there was no difference of 90-day or
overall mortality (P = 0.67 and 0.42, respectively), (2)
mean intra-operative blood loss or transfusion needs
were similar (P = 0.99), (3) mean operation time of MS
was shorter 21.7 minutes in comparison with VATS (P
< 0.001), (4) intra-operative complications and hypoxe-
mia of MS was less in comparison with VATS (P =
0.02, P = 0.004), (5) hospital stay of post LVRS was
l o n g e rf o rM St h a nV A T S( P = 0.01), (6) at postopera-
tive 30 days, independently living patients were less for
MS than VATS (P = 0.02), (7) there was no appreciable
difference in lung function between the two approaches
after follow-up 12 and 24 months, (8) costs for either
operation or the associated hospital stay were less for
VATS than for MS (P < 0.01).
Table 1 Summary of RCTs on conservative medical therapy and LVRS
Author Year published Cases (N) Imaging diagnosis Cases underwent conservative
medical therapy (n)
Cases underwent LVRS(n)
Criner, G. 1999 37 CT scan 18 19
J[16] Geddes, D[12] 2000 48 CT scan 24 24
Pompeo, E. [17] 2000 60 CT scan 30 30
Fishman, A [18] 2003 1218 CT scan 608 610
Goldstein, R. S [19] 2003 55 CT and V/Q scan* 28 27
Mineo[20] 2004 60 CT scan 30 30
Hillerdal, G. [2] 2005 106 CT and V/Q Scan* 53 53
Miller, J. D[21] 2005 93 CT and V/Q Scan* 58 35
*: V/Q scan, also known as lung scan, which evaluates both the Ventilation and Perfusion of the lungs using scintigraphy and medical isotopes. Q is the symbol
for perfusion which represents the movement of blood through the arteries that supply the lung.
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buttressing, autologous fibrin sealant and BioGlue during
LVRS
In 2000, a RCT [23] was conducted in 65 patients
underwent bilateral lung volume reduction surgery by
VATS, either without (control group) or with bovine
pericardium for buttressing. The RCT demonstrated
using bovine pericardium significantly decrease the
median air leak time compared with control group (0.0
day [range, 0 to 28 days versus 4 days [range, 0 to 27
days); p < 0.001), as well as median drainage time (5
days [range, 1 to 35 days] versus 7.5 days [range, 2 to 29
days); P=0.045).
In 2008, a RCT [15] was conducted in 25 patients
undergoing bilateral LVRS by VATS. The result indi-
cated that mean value of the total severity scores of air
leak for the first 48 hours postoperative was significant
lower in the treated side (with using autologous fibrin
sealant) than in the control side (without using autolo-
gous fibrin sealant) (P < 0.01), independently of the
length of the resection. Prolonged air leak and mean
duration of drainage were also significantly reduced in
the treated group compared with the control group
(4.5% and 2.8 ± 1.9 days versus 31.8% and 5.9 ± 2.9
days, respectively)(P = 0.03, P < 0.01).
In 2009, a pilot RCT [14] was conducted in ten
patients undergoing LVRS via MS approach. Each case
was treated with BioGlue on one side randomly and
pericardial buttress on the other side as an adjunct to
the staple line. The result suggested that BioGlue treated
side had the shorter mean duration of air-leak (3.0 ± 4.6
vs 6.5 ± 6.9 days), lesser chest drainage volume(733 ±
404 vs 1001 ± 861 ml) and shorter time to chest drain
removal (9.7 ± 10.6 vs 11.5 ± 11.1 days) compared with
pericardial buttress side.
Discussion
World Health Organization suggested that emphysema
will probably become the third cause of death with
cigarette smoking [24]. More and more studies are
focusing on the treatment of emphysema which is still
untoward. Conservative medical therapies can not pro-
vide satisfactory long term therapeutic efficacy [5]. With
regard to LVRS, the mortality and efficacy is still con-
troversial. Therefore, we deem it essential to synthesize
the published RCTs, evaluate safety, assess short-term
efficacy and long-term sequel of LVRS by systemic
review and meta-analysis.
Meta-analysis suggested that postoperative mortality
of LVRS group gradually decreased from 3 months to
12 months. In the initial three months, the mortality of
LVRS group was significantly higher than conservative
treatment group due to respiratory failure and pulmon-
ary infection [2,12,16-21]. However, there was no signifi-
cant difference on mortality between the two aforesaid
groups until the 12 months. NETT [25] suggested that
Table 2 A summary of lung function, gas exchange, DLCO% and 6MWD of five RCTs on the 3
rd,6
th,1 2
th postoperative
month
Variables Postoperative follow-up (month) No of RCTs No of total patients GroupA/B WMD95%CI p-value
3 2[12,16] 80 39/41 0.23(0.08,0.37) 0.002
FEV1 6 3[2,17,19] 180 89/91 0.32(0.23,0.41) <0.00001
12 3[2,17,19] 169 65/64 0.28(0.20,0.36) <0.00001
3 2[12,16] 80 39/41 11.31(6.29,15.69) <0.00001
FEV1% 6 3[2,17,19] 180 89/91 10.16(7.42,12.89) <0.00001
12 3[2,17,19] 167 85/82 7.65(4.97,10.33) <0.00001
3 2[12,16] 80 39/41 -54.44(-75.23, -33.85) <0.00001
RV% 6 3[2,17,19] 170 87/83 - 54.09( - 64.66, -43.52) <0.00001
12 3[2,17,19] 166 86/80 - 53.42( - 63.74, -43.10) <0.00001
TLC% 3 2[12,16] 80 39/41 - 21.70( - 30.98, -12.42) <0.00001
6 2[2,19] 115 59/56 - 15.73( - 22.44, -9.02) <0.00001
12 3[2,17,19] 120 59/61 - 16.24( - 23.07, -9.41) <0.00001
DLCO% 6 2[17,19] 105 52/53 0.01(-0.25,0.27) 0.95
12 2[17,19] 96 51/45 0.01(-0.25,0.27) 0.25
Pa02 6 2[17,19] 136 67/6 9.98(9.65,10.13) <0.00001
12 2[2,17] 114 60/54 6.37(6.10,6.64) <0.00001
PaC02 6 4[2,11,17,21] 229 108/121 - 1.54(- 1.72, - 1.36) <0.00001
12 2[2,17] 114 60/54 -2.00(-2.23, -1.77) <0.00001
3 2[12,16] 80 39/41 10.5(-16.30,37.38) 0.44
6MWD 6 5[2,11,17,19 ,21] 274 129/145 68.34(36.58,100.09) <0.00001
12 3[2,17,19] 168 85/83 76.92(60.87,92.98) <0.00001
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predicted value with either homogeneous emphysema or
DLCO% <20%, lead to higher thirty-day and overall
mortality. In addition, Fishman et al. [18] suggested
mortality in three months following LVRS was lower in
the patients suffering from upper-lobe emphysema com-
bining low exercerise capacity even compared with con-
servative treatment group, probably due to clearer target
areas or more accessible areas for surgical excision.
Intriguingly, Fishman et al. [18] demonstrated that over-
vall mortality of LVRS group (except high risk patients)
was statistically lower than of conservative treatment
group after 5 years follow up.
Meta-analysis also suggested lung function indices of
LVRS group were appreciably improved on the 3
th,6
th
and 12
th postoperative month, compared with conserva-
tive treatment group, in accordance to results of Fish-
man’s study [18]. With regard to DLCO %, there was
not appreciablly difference between two groups (P >
0.05), consisting with outcomes of Geddes’s study [12].
However, only two RCTs mentioned DLCO %, and
more data should be accumulated.
The effect of LVRS on PaO2 and PaCO2 was still con-
troversial. For instance, Geddes’s study [12] demon-
strated insignificant improvment of PaO2 and PaCO2
following LVRS. Snyder’s study [26] manifested that
LVRS can increase PaO2 efficaciously (P >0 . 0 0 1 )
(PaCO2 not shown). In addtion, Cremona et al. [27]sug-
gested that LVRS improved PaO2, without significant
effect on PCO2. However, our meta-analysis demon-
strated that LVRS can increase PaO2 and decrease
PaCO2 appreciably.
With respect to 6MWD, we concluded that LVRS can
obviously increase exercise capacity on the 6
th and 12
th
postoperative month, in accordance to outcomes of
Fishman’s [18] and Geddes’s study [12]. Naunheim et al.
[28] reported that improvement of post-operative exer-
cise capacity can be maintained up to 3 years, especially
in upper-lobe emphysema combining low exercise
capacity.
Despite the different assessment criterion of the seven
included RCTs, all the studies concluded that LVRS can
improve QOL efficaciously. Krachman et al. [29] found
that in patients with severe emphysema, LVRS, but not
continued optimal medical therapy, results in improved
sleep quality and nocturnal oxygenation. Kozora et al.
[30] found that LVRS group demonstrated improvement
in specific neuropsychological functions, depression,
anxiety compared with conservative treatment group
due to the unclear mechanisms. Additionally, compared
with medical therapy, LVRS reduces the frequency of
COPD exacerbations, increases the time to first exacer-
bation, and has a significant effect on the composite
QOL survival endpoint tested [31,32].
The published RCT [13] concluded that morbidity and
mortality were similar following either MS or VATS, as
well as pulmonary function indices. Additionally,
another study [33] suggested that two techniques offered
similar outcomes regarding postoperative pain and com-
plications, but VATS allowed earlier recovery at a lower
cost than MS.
A variety of biologic and synthetic materials have been
utilized to prevent and minimize air leak, including but-
tressing materials for instance bovine pericardium, poly-
tetrafluoroethylene(PTFE), Teflon, polyglycollic acid and
gel foam [14,15,23]. In patients suffering from severe
emphysema and undergoing LVRS, buttressing of staple
lines with bovine pericardial strips are traditionally and
routinely used to reduce air leaks from rarefied emphy-
sematous lung tissue. However, its efficacy remains
inconclusive. Hazelrigg’s study [34] suggested that using
buttressing reduced 2 to 3 days of hospital stay. And
Stammberger’s RCT [23] indicated a statistically signifi-
cant reduction in air leak duration after bilateral, but-
tressed, thoracoscopic LVRS, in spite of no reduction in
length of stay. However, Moser et al. [15] pointed that
buttressing adjuncts might result in the extensive
inflammatory reaction with formation of dense adhe-
sions, which enhances difficulty of lung transplantation
after LVRS. And Moser et al. [15] suggested that autolo-
gous fibrin sealant overcomes the potential infective and
antigenic risk in comparison to using pooled human
fibrinogen or exogenous thrombin, especially of bovine
origin. Besides, the results of Rathinam’s study [14] also
prefer BioGlue to conventional buttresses in terms of
reduction in air-leak, chest drainage volumes, duration
of chest drainage and significant absence of complica-
tions. Recently, a new rigid applicator tip (CryoLife Inc,
U.S.A), 34 cm in length, is developed and enables pre-
cise delivery in VATS. We deem BioGlue and autolo-
gous fibrin sealant the efficacious methods to reduce air
leak following LVRS.
Currently, a variety of novel, less invasive broncho-
scopic lung volume reductions (BLVR) has proceeded to
human trials including one-way occlusive valves, sclero-
sant biogels, and endobronchial bypass tract formation
[10,35]. However, current data available in the small,
nonrandomized studies only showed short-term
improvement of dyspnoea and quality of life post
BLRV [10]. Thus, further RCTs are required regarding
the comparison of BVRL and LVRS [36].
Collectively, LVRS offers the more benefits regarding
survival, lung function, gas exchange, exercise capacity
and QOL, despite high postoperative mortality in initial
three months. As a result, LVRS should be duly recom-
mended to patients with severe emphysema and without
high risk factors. With regard to LVRS approaches, we
prefer VATS to MS, due to the earlier recovery and
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BioGlue an efficacious method to reduce air leak follow-
ing LVRS.
Abbreviation
LVRS: (Lung volume reduction surgery); RCTs: (rando-
mized controlled trials); VATS: (video-assisted thoraco-
scopic surgery); MS: (median sternotomy); FEV1: (forced
expiratory volume in one second); RV: (residual
volume); TLC: (total lung capacity); PaO2: (pressure of
arterial partial oxygen); PaCO2: (pressure of arterial
CO2); DLCO: (Diffusion capacity of the lung for carbon
monoxide); 6MWD: (six-minute walk distance); QOL:
(Quality of life); FEV1: (forced expiratory volume in one
second); FEV1%: (percentage of predicted values for
FEV1); RV%: (percentage of predicted values for residual
volume); TLC%: (percentage of predicted values for total
lung capacity);
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